Ebola Antibody May Be Ineffective Against Bundibugyo Virus in 2026 Outbreak

A recent study published in Nature Communications suggests that an approved Ebola antibody may not be effective against the Bundibugyo virus (BDBV) responsible for the emerging 2026 outbreak. Structural analyses revealed that BDBV has evolved significant glycoprotein substitutions, including novel mutations, that could cause the antibody to dock off-target. This highlights the importance of testing treatments against specific viral species.